Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, announced a multi-program collaboration with a San Diego-based...
Skye Bioscience, Inc., and Redx Pharma Limited (“Redx”), a U.K. based, privately-held clinical-stage biotechnology company focused on develop...
Marks Third NMPA Approval in China for an Ivonescimab-Containing Regimen NMPA Approval Based on HARMONi-6 Clinical Trial Conducted by Akeso in China ...
CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM). Under...
QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour...
The U.S. Food and Drug Administration granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral t...
MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus A...
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical T...
Nanjing Leads Biolabs Co., Ltd. announced that its Phase II clinical study evaluating Opamtistomig (LBL-024), a proprietary PD-L1/4-1BB bispecific antibo...
Immunologically "cold" tumors remain one of the greatest challenges in oncology, limiting the effectiveness of checkpoint inhibitors in cancers such as pla...
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Sanofi announced that the Europ...
Nurix Therapeutics, Inc. announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093) evaluating b...
Novo Nordisk today announced headline results from the ZEUS cardiovascular outcomes phase 3 trial. While ziltivekimab demonstrated target engagemen...
© 2026 Biopharma Boardroom. All Rights Reserved.
